The UK and US have concluded a significant trade agreement that will keep zero tariffs on UK pharmaceutical exports being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that tariffs on these crucial products will be held at zero for a duration of three years.
This deal follows earlier warnings to hike tariffs on patented pharmaceutical products, with increases floated reaching double the cost.
"This deal between the Britain bolsters the international landscape for new treatments and introduces long-overdue balance to U.S.–U.K. medicine commerce," a release declared.
Trade Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the United States, which is clearly the largest destination for large companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to last September, the UK shipped medicines valued at billions to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects employment, increases investment and facilitates the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several key changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be restricted at 15%. Last year, repayments exceeded 20%.
Broader Context
The deal comes amid a ongoing dispute between the drug companies and the British authorities over spending levels and regulatory access.
The disagreement were exacerbated by arguments that US customers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several major manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been pledged toward American operations.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
